Soleno Therapeutics to Be Acquired by Neurocrine Biosciences

The latest update is out from Soleno Therapeutics ( (SLNO) ).

On April 5, 2026, Soleno Therapeutics agreed to be acquired by Neurocrine Biosciences, which will launch a cash tender offer at $53.00 per share, valuing Soleno’s equity at about $2.9 billion and representing a premium of roughly 34% to Soleno’s April 2 close. The deal, unanimously approved by both boards and supported by tender agreements from key Soleno shareholders, is expected to close within 90 days of the April 6, 2026 announcement, subject to majority tender, antitrust clearance and other customary conditions.

Upon completion, Soleno will merge into a Neurocrine subsidiary and become a wholly owned unit, with all remaining shares converted into the same $53.00 cash consideration and in‑the‑money stock options cashed out at the offer price. The transaction will add VYKAT XR, a fast‑growing, first‑in‑class Prader–Willi syndrome therapy with $190 million in 2025 sales, to Neurocrine’s existing INGREZZA and CRENESSITY franchises, broadening its rare‑disease endocrinology portfolio and creating a more diversified, durable revenue base supported by expected cost synergies and extended VYKAT XR patent life.

The most recent analyst rating on (SLNO) stock is a Hold with a $42.00 price target. To see the full list of analyst forecasts on Soleno Therapeutics stock, see the SLNO Stock Forecast page.

Spark’s Take on SLNO Stock

According to Spark, TipRanks’ AI Analyst, SLNO is a Neutral.

The score is driven primarily by the sharp 2025 financial inflection (revenue scale, profitability, positive free cash flow) and positive earnings-call momentum on launch execution and liquidity. These strengths are tempered by weak technicals (price below key moving averages with negative MACD) and a high P/E with no dividend support, which increases sensitivity to any slowdown or regulatory/commercial setbacks.

To see Spark’s full report on SLNO stock, click here.

More about Soleno Therapeutics

Soleno Therapeutics is a biopharmaceutical company focused on endocrinology and rare diseases, most notably Prader–Willi syndrome, a rare genetic neurodevelopmental disorder affecting about 10,000 patients in the U.S. Its lead product, VYKAT XR (diazoxide choline), is the first and only FDA‑approved treatment for hyperphagia in Prader–Willi syndrome and generated $190 million in revenue in 2025. Soleno listed on Nasdaq as SLNO and has positioned VYKAT XR as a foundational first‑line therapy supported by intellectual property expected to extend into the mid‑2040s.

Average Trading Volume: 1,688,816

Technical Sentiment Signal: Sell

Current Market Cap: $2.04B

For a thorough assessment of SLNO stock, go to TipRanks’ Stock Analysis page.